Neoplasm

EQS-News: Eckert & Ziegler Extends Ga-68 Activities in Japan

Retrieved on: 
Wednesday, March 13, 2024

Berlin, Germany – 28 February 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) expands its activities on Gallium-68 (Ga-68) labeled diagnostics in Japan together with Novartis Pharma K.K.

Key Points: 
  • Berlin, Germany – 28 February 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) expands its activities on Gallium-68 (Ga-68) labeled diagnostics in Japan together with Novartis Pharma K.K.
  • (Japan).
  • For this purpose, a clinical trial was notified with the Japanese Pharmaceuticals and Medical Devices Agency (PMDA), stating Eckert & Ziegler’s proprietary Ge-68/Ga-68 generator GalliaPharm® as the single source for Ga-68.
  • “We are happy to extend our radioisotope supply business in Japan by contributing our GalliaPharm® to this important clinical research project,” explained Dr. Harald Hasselmann, CEO of Eckert & Ziegler AG.

EQS-News: Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®

Retrieved on: 
Wednesday, March 13, 2024

BERKELEY, US – MAINZ, Germany – February 22nd, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, is pleased to announce a distribution partnership with Praxisdienst, Germany’s largest online retailer for medical products.

Key Points: 
  • BERKELEY, US – MAINZ, Germany – February 22nd, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, is pleased to announce a distribution partnership with Praxisdienst, Germany’s largest online retailer for medical products.
  • This partnership will harness Praxisdienst's extensive distribution network alongside Mainz Biomed's leading-edge diagnostic technologies, ensuring broader access to their sophisticated medical solutions for healthcare professionals and patients throughout Germany.
  • Darin Leigh, CCO of Mainz Biomed, expressed enthusiasm about the partnership: "We are delighted to partner with Praxisdienst to distribute ColoAlert®, our innovative at-home screening test for colorectal cancer.
  • For more information about Mainz Biomed and our innovative products, please visit Mainz Biomed's website .

Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024

Retrieved on: 
Monday, March 11, 2024

SEATTLE, March 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will host an in-person and virtual analyst day at the New York Stock Exchange on Monday, March 18, 2024 at 10:00 AM ET.

Key Points: 
  • SEATTLE, March 11, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will host an in-person and virtual analyst day at the New York Stock Exchange on Monday, March 18, 2024 at 10:00 AM ET.
  • To register, click here .
  • In addition, the Company’s management will discuss its next radiotherapy compound in development and provide an overview of its promising novel pretargeting technology.
  • A live question and answer session will follow the formal presentations.

Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board

Retrieved on: 
Thursday, March 7, 2024

SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the “SAB”).

Key Points: 
  • SAN DIEGO and SUZHOU, China, March 07, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announced the appointment of Heinz-Josef Lenz, M.D., FACP, to its Scientific and Strategic Advisory Board (the “SAB”).
  • Dr. Lenz accelerates translational and clinical research and provides training and mentoring in the design and implementation of investigator-initiated trials.
  • In 1991, he completed his internship, residency, and fellowship training at the Eberhardt Karls Universität in Tübingen, Germany.
  • “His insight and clinical experience as a leading expert in colorectal cancer is of great importance as we develop our SAFEbody® ADG126 for patients worldwide.”
    For more information about members of the Adagene Scientific and Strategic Advisory Board, visit: https://www.adagene.com/about/key-advisors/

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

Retrieved on: 
Thursday, March 7, 2024

“In 2023 we initiated a combination study with FHD-286 in AML, with data anticipated in the second half of 2024.

Key Points: 
  • “In 2023 we initiated a combination study with FHD-286 in AML, with data anticipated in the second half of 2024.
  • The IND is planned for the second quarter of 2024, with an initial focus in non-small cell lung cancer.
  • The Company is conducting preclinical work to further explore the opportunity and expects data in the second quarter of 2024.
  • Foghorn is presenting new preclinical data for its CBP and EP300 selective degrader programs at the 2024 AACR Annual Meeting, April 5-10, 2024.

Alpha Tau Medical Announces Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 7, 2024

We are also exploring the addition of new clinical trials in the U.S., based upon recent positive regulatory feedback.

Key Points: 
  • We are also exploring the addition of new clinical trials in the U.S., based upon recent positive regulatory feedback.
  • The Alpha DaRT procedure was deemed technically successful in all five cases, with Alpha DaRT sources successfully inserted into the target tumors.
  • Targeting completion of patient recruitment in the ReSTART pivotal U.S. multi-center trial in recurrent cutaneous squamous cell carcinoma in H2 2024.
  • The Company expects that this cash balance will be sufficient to fund operations for at least two years.

Enterome Announces Upcoming Presentation on OncoMimics™ Approach to Cancer Immunotherapy at the AACR Annual Meeting 2024

Retrieved on: 
Wednesday, March 6, 2024

The poster will be presented by Dr. Vincent Panneton, Postdoctoral Associate in Pharmacology at the Ludwig Collaborative Laboratory led by Dr. Taha Merghoub and Dr. Jedd Wolchok at Weill Cornell Medicine.

Key Points: 
  • The poster will be presented by Dr. Vincent Panneton, Postdoctoral Associate in Pharmacology at the Ludwig Collaborative Laboratory led by Dr. Taha Merghoub and Dr. Jedd Wolchok at Weill Cornell Medicine.
  • “We are pleased to announce the presentation of these promising preclinical data which provide novel insights into the design of OncoMimics™ peptides for both neoantigens and tumor-associated antigens.
  • These results serve as an early validation of our approach to novel cancer immunotherapies,” said Laurent Chêne, Head of Drug Discovery at Enterome.
  • The abstract will be published in an online supplement to Cancer Research, the official journal of the American Association for Cancer Research, on March 22nd, and the poster will be available on Enterome’s website after the AACR Meeting.

Ludwig Enterprises Inc. (OTC:LUDG) Announces Patent Filing for Breakthrough in Identifying mRNA Genes Associated with Certain Cancers

Retrieved on: 
Wednesday, March 6, 2024

The Company’s mRNA for Life™ is a one-of-the-kind noninvasive at-home sceening test for genes that could be associated with cancer.

Key Points: 
  • The Company’s mRNA for Life™ is a one-of-the-kind noninvasive at-home sceening test for genes that could be associated with cancer.
  • This test allows a person to make themselves a priority and could be a signal to seek a medical examination.
  • The Company selected for measurement 48 distinct mRNA genes in stored specimens from patients afflicted with breast, bladder or colorectal cancer.
  • mRNA levels were analyzed using machine learning artificial intelligence (AI) to identify markers of genetic expression involved in separate cancers.

Auron Announces Poster Presentations at 2024 AACR Annual Meeting

Retrieved on: 
Wednesday, March 6, 2024

Auron will share data demonstrating the ability of AURIGIN to identify drivers of tumor plasticity, a critical vulnerability of cancer cells that is associated with poor prognosis and treatment-resistance.

Key Points: 
  • Auron will share data demonstrating the ability of AURIGIN to identify drivers of tumor plasticity, a critical vulnerability of cancer cells that is associated with poor prognosis and treatment-resistance.
  • AURIGIN utilizes a single cell multi-omics atlas of human development and AI machine learning to identify the most relevant genetic targets in cancer cell plasticity.
  • Using AURIGIN to identify disrupted cell states, Auron is developing targeted treatments to revert cancer cells to a normal, quiescent state to stop tumor growth and proliferation.
  • At AACR, Auron will also present in vitro and in vivo data from its first-in-class, novel program targeting KAT2A/B, a histone acetyltransferase identified by AURIGIN that is associated with multiple tumor types.

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, March 6, 2024

The one-year mark is a meaningful milestone for patients as the likelihood of relapse is now much lower, leading to an improved quality of life.

Key Points: 
  • The one-year mark is a meaningful milestone for patients as the likelihood of relapse is now much lower, leading to an improved quality of life.
  • With recent FDA clearance of our INDs for TSC-201-B0702 and TSC-204-A0101, we now have six TCR-Ts cleared for clinical development.
  • Data showed that all eight (100%) treatment-arm patients were free from relapse, including four patients with follow-up beyond ten months.
  • The Company will present two “Trials in Progress” poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024.